Vivo Bio Tech Ltd — Important, 06-01-2026: Company Update

The company has allotted 90,000 new equity shares following the conversion of warrants previously issued on a preferential basis. This action marks the exercise of these warrants by investors, leading to an increase in the company's total outstanding share capital. This is a routine capital market activity that reflects commitments made by warrant holders and can broaden the shareholder base.